Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Drug Memories in Cocaine Use Disorder
NCT05978167Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2023
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in cocaine use disorder (CUD) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: fMRI blood-oxygenation level dependent signal at Day 1. Started Jun 2023; status: active, not recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT05978167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978167.